

Ceres, Inc.
Form 10-Q
January 13, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended November 30, 2014

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934**

For the Transition Period from _____ to _____

Commission File Number: 001-35421

Edgar Filing: Ceres, Inc. - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, Ceres, Inc. qualifies as an “emerging growth company,” as defined under the JOBS Act.

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

| Class | Outstanding at January 8, 2015 |
|------------------------------------------|---------------------------------------|
| Common Stock, \$0.01 par value per share | 48,261,466 |

TABLE OF CONTENTS

| | Page |
|------------------------------------------------------------------------------------------------------|-------------|
| <u>PART I: FINANCIAL INFORMATION</u> | 2 |
| ITEM 1. <u>Condensed Consolidated Financial Statements (unaudited)</u> | 2 |
| ITEM 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 16 |
| ITEM 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u> | 27 |
| ITEM 4. <u>Controls and Procedures</u> | 28 |
| <u>PART II: OTHER INFORMATION</u> | 29 |
| ITEM 1. <u>Legal Proceedings</u> | 29 |
| ITEM 1A. <u>Risk Factors</u> | 29 |
| ITEM 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 29 |
| ITEM 3. <u>Defaults Upon Senior Securities</u> | 29 |
| ITEM 4. <u>Mine Safety Disclosures</u> | 29 |
| ITEM 5. <u>Other Information</u> | 29 |
| ITEM 6. <u>Exhibits</u> | 29 |

PART I: FINANCIAL INFORMATION**Item 1. Financial Statements.****CERES, INC. AND SUBSIDIARIES****Condensed Consolidated Balance Sheets****(In thousands, except share amounts and par value)****(Unaudited)**

| | November 30, 2014 | August 31, 2014 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 4,254 | \$ 3,423 |
| Marketable securities | 17,343 | 24,579 |
| Prepaid expenses | 606 | 633 |
| Accounts receivable | 321 | 370 |
| Inventories | 790 | 84 |
| Other current assets | 375 | 240 |
| Total current assets | 23,689 | 29,329 |
| Property and equipment, net | 2,767 | 2,996 |
| Other assets | 102 | 99 |
| Total assets | \$ 26,558 | \$ 32,424 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Accounts payable and accrued expenses | \$ 3,743 | \$ 4,278 |
| Other current liabilities | 464 | 374 |
| Current portion of long-term debt | 55 | 70 |
| Total current liabilities | 4,262 | 4,722 |
| Other non-current liabilities | 70 | 75 |
| Long-term debt, net of current portion | - | 18 |
| Total liabilities | 4,332 | 4,815 |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Common stock and additional paid in capital, \$0.01 par value; 240,000,000 shares authorized; 48,261,466 shares issued and outstanding at November 30, 2014; 48,192,883 shares issued and outstanding at August 31, 2014 | 332,725 | 332,109 |

Edgar Filing: Ceres, Inc. - Form 10-Q

| | | | | |
|--------------------------------------------|-----------|---|-----------|---|
| Accumulated other comprehensive loss | (621 |) | (595 |) |
| Accumulated deficit | (309,878 |) | (303,905 |) |
| Total stockholders' equity | 22,226 | | 27,609 | |
| Total liabilities and stockholders' equity | \$ 26,558 | | \$ 32,424 | |

See accompanying notes to the unaudited condensed consolidated financial statements.

CERES, INC. AND SUBSIDIARIES**Condensed Consolidated Statements of Operations****(In thousands, except share and per share amounts)****(Unaudited)**

| | Three months ended November 30, 2014 | | 2013 | |
|-----------------------------------------------------------------------------------|--------------------------------------------|---|------------|---|
| Revenues: | | | | |
| Product sales | \$ - | | \$ 20 | |
| Collaborative research and government grants | 400 | | 743 | |
| Total revenues | 400 | | 763 | |
| Cost and operating expenses: | | | | |
| Cost of product sales | 442 | | 1,309 | |
| Research and development | 2,504 | | 4,414 | |
| Selling, general and administrative | 3,441 | | 3,260 | |
| Total cost and operating expenses | 6,387 | | 8,983 | |
| Loss from operations | (5,987 |) | (8,220 |) |
| Interest expense | (3 |) | - | |
| Interest income | 18 | | 16 | |
| Loss before income taxes | (5,972 |) | (8,204 |) |
| Income tax expense | (1 |) | (1 |) |
| Net loss | \$ (5,973 |) | \$ (8,205 |) |
| Basic and diluted net loss per share attributable to common stockholders | \$ (0.12 |) | \$ (0.33 |) |
| Weighted average outstanding common shares used for net loss per share : | | | | |
| Basic and diluted | 48,256,820 | | 25,106,690 | |

See accompanying notes to the unaudited condensed consolidated financial statements.

CERES, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

| | Three months ended | |
|-----------------------------------------------|--------------------|-------------|
| | November 30, | |
| | 2014 | 2013 |
| Net loss | \$ (5,973) | \$ (8,205) |
| Other comprehensive income (loss) | | |
| Foreign currency translation adjustments | (30) | 104 |
| Net unrealized gains on marketable securities | 4 | 5 |
| Total comprehensive loss | \$ (5,999) | \$ (8,096) |

See accompanying notes to the unaudited condensed consolidated financial statements.

CERES, INC. AND SUBSIDIARIES**Condensed Consolidated Statements of Cash Flows****(In thousands)****(Unaudited)**

| | Three months ended November 30, | |
|-----------------------------------------------------------------------------|------------------------------------|-------------|
| | 2014 | 2013 |
| Cash flows from operating activities: | | |
| Net loss | \$ (5,973) | \$ (8,205) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Net gain on disposal of assets | (23) | (54) |
| Depreciation | 189 | 414 |
| Amortization of premiums on marketable securities | 63 | 84 |
| Non-cash interest income | (75) | (99) |
| Stock compensation | 615 | 922 |
| Changes in operating assets and liabilities: | | |
| Prepaid expenses | 57 | 66 |
| Accounts receivable | 47 | 57 |
| Inventories | (749) | 21 |
| Other assets | (200) | 20 |
| Accounts payables and accrued expenses | (351) | 904 |
| Other liabilities | 85 | 57 |
| Other | 22 | 137 |
| Net cash used in operating activities | (6,293) | (5,676) |
| Cash flows from investing activities: | | |
| Purchases of property and equipment | (149) | (406) |
| Proceeds from sale of property and equipment | 23 | 54 |
| Purchases of marketable securities | (720) | (5,698) |
| Maturities of marketable securities | 7,950 | 10,090 |
| Net cash provided by investing activities | 7,104 | 4,040 |
| Cash flows from financing activities: | | |
| Repayment of debt | (23) | (46) |
| Net cash used in financing activities | (23) | (46) |
| Effect of foreign currency translation on cash | 43 | 115 |
| Net increase (decrease) in cash and cash equivalents | 831 | (1,567) |
| Cash and cash equivalents at beginning of period | 3,423 | 8,881 |
| Cash and cash equivalents at end of period | \$ 4,254 | \$ 7,314 |

See accompanying notes to the unaudited condensed consolidated financial statements.

CERES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands, except share and per share data)

1) The Company

Ceres, Inc. (Company) is an agricultural biotechnology company that develops and markets seeds to produce crops for bioenergy and other markets that utilize plant biomass. The Company uses a combination of advanced plant breeding and biotechnology to develop seed products. These technology platforms, which can increase crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple crops, including food, feed, fiber and fuel crops.

In January 2010, the Company formed a subsidiary, Ceres Sementes do Brasil Ltda. The Company's ownership in this subsidiary is 99.9% and the Company's Chief Executive Officer owns the remaining interest. In May 2014, the Company formed a wholly owned subsidiary, Ceres Agrotechnologies Intl LLC. In May 2014, the Company also formed a subsidiary, CS Semillas de Mexico, S.de L. de C.V. The Company's ownership in this subsidiary is 99.9% and Ceres Agrotechnologies Intl LLC owns the remaining interest.

The Company has incurred substantial net losses from operations since its inception and its accumulated deficit as of November 30, 2014 was \$309,878. The Company expects to incur additional losses related to the continued development and expansion of its business, including research and development, seed production and operations, and sales and marketing.

During the first quarter of fiscal 2014, management commenced the implementation of a plan (Plan) intended to further align expenditures with the Company's near-term commercial opportunity in Brazil, shift Northern Hemisphere sorghum breeding activities from College Station, Texas to a more appropriate location, de-emphasize research and development for U.S. cellulosic feedstocks, reduce costs and conserve cash. The actions taken under the Plan, which included, among others, a workforce reduction that impacted 16 positions in the U.S, were completed at August 31, 2014.

On March 10, 2014, the Company completed a registered public offering of 23,000,000 shares of its common stock (including 3,000,000 shares purchased by the underwriter upon the exercise in full of their right to purchase up to an additional 3,000,000 shares to cover over-allotments) at a price to the public of \$1.00 per share. The Company received approximately \$20.8 million of proceeds from the offering, after deducting underwriting discounts and

commissions and estimated offering expenses.

The Company plans to finance its operations for the next 12 months with cash and marketable securities on hand, and with cash inflows from collaboration and grant funding and from product sales. The Company intends to seek additional funds through collaborations, licensing arrangements, public or private debt or equity financings or government programs, and may also seek to reduce expenses related to our operations. The Company cannot assure you that such additional funds from collaborations, licensing arrangements, public or private debt or equity financings or government programs will be available or that the terms would be acceptable to the Company. There is also no assurance that the Company will achieve profitable operations, or if achieved, that it can sustain them on a continued basis.

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (GAAP) and with the instructions for Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's Form 10-K for the fiscal year ended August 31, 2014 filed with the Securities and Exchange Commission (SEC) on November 20, 2014.

CERES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands, except share and per share data)

The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.

Principles of Consolidation

The condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

In preparing the unaudited condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include the valuation of property and equipment, common stock and stock options. Actual results could differ from those estimates.

Fair Value of Financial Instruments

Assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels that are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

- Level 3 inputs are unobservable inputs for the asset or liability.

The following tables present the Company's financial assets that were measured at fair value on a recurring basis as of November 30, 2014 and August 31, 2014 by level within the fair value hierarchy:

| | November 30, 2014 | | | |
|--------------------------------------------|-------------------|----------|---------|----------|
| | Level 1 | Level 2 | Level 3 | Total |
| Financial Assets | | | | |
| Money Market Funds | \$67 | \$— | \$ — | \$67 |
| Certificates of Deposit—available for sale | — | 3,762 | — | 3,762 |
| Corporate Bonds—available for sale | — | 13,641 | — | 13,641 |
| Total | \$67 | \$17,403 | \$ — | \$17,470 |

All of the money market funds and \$60 of the certificates of deposit are included in cash and cash equivalents on the condensed consolidated balance sheets.

CERES, INC. AND SUBSIDIARIES**Notes to Condensed Consolidated Financial Statements (Unaudited)****(In thousands, except share and per share data)**

| | August 31, 2014 | | | Total |
|--------------------------------------------|-----------------|----------|---------|----------|
| | Level 1 | Level 2 | Level 3 | |
| Financial Assets | | | | |
| Money Market Funds | \$2,114 | \$— | \$ — | \$2,114 |
| Certificates of Deposit—available for sale | — | 4,240 | — | 4,240 |
| Commercial Paper—available for sale | — | 5,249 | — | 5,249 |
| Corporate Bonds—available for sale | — | 15,150 | — | 15,150 |
| Total | \$2,114 | \$24,639 | \$ — | \$26,753 |

All of the money market funds and \$60 of the certificates of deposit are included in cash and cash equivalents on the condensed consolidated balance sheets.

Accounts Receivable

Accounts receivable represents amounts owed to the Company from product sales and collaborative research and government grants. The Company had no amounts reserved for doubtful accounts at November 30, 2014 and August 31, 2014 as the Company expects full collection of the accounts receivable balances.

Inventories

At November 30, 2014, inventory consisted of finished seed inventory and unharvested biomass in Brazil. The costs for finished seed inventory are related to sorghum seeds. The costs for unharvested biomass are related to the Company's biomass contracts. At August 31, 2014, seed inventory consisted of work-in-process costs and finished goods for costs related to the Company's sorghum seeds in Brazil.

When inventory costs exceed expected market value due to obsolescence or lack of demand, inventory write-downs are recorded for the difference between the cost and the market value in the period based on the Company's evaluation of such inventory.

Property and Equipment

Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the shorter of the estimated useful lives or the remaining life of the lease. Depreciation periods for the Company's property and equipment are as follows:

| | |
|----------------------------------------------------------------|-------------|
| Automobiles and trucks | 3-5 years |
| Office, laboratory, farm and warehouse equipment and furniture | 3-5 years |
| Leasehold improvements | 3-10 years |
| Buildings | 14-39 years |

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To the extent that an impairment indicator has occurred, recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the reporting periods presented herein there was no impairment.

Foreign Currency Translation

The Brazilian Real is the functional currency of the Company's subsidiary in Brazil. Accordingly, assets and liabilities of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. Revenues and expenses are translated at the weighted average rate of exchange during the reporting period. Gains and losses from foreign currency translation adjustments are represented as a component of accumulated other comprehensive loss within the Company's condensed consolidated balance sheets.

CERES, INC. AND SUBSIDIARIES**Notes to Condensed Consolidated Financial Statements (Unaudited)****(In thousands, except share and per share data)*****Accumulated Other Comprehensive Loss***

The Company's unrealized gains and losses on available-for-sale securities and foreign currency translation adjustments represents the components of comprehensive loss and have been disclosed in the condensed consolidated balance sheets.

The following summarizes the changes in the balances of each component of accumulated other comprehensive loss during the three months ended November 30, 2014:

| | Foreign Currency Translation | Unrealized Gains (Losses) on Securities | Accumulated Other Comprehensive Loss |
|------------------------------|------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Balance at August 31, 2014 | \$ (584) | \$ (11) | \$ (595) |
| Comprehensive income (loss) | (30) | 4 | (26) |
| Balance at November 30, 2014 | \$ (614) | \$ (7) | \$ (621) |

Basic and Diluted Net Loss Per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding, to the extent they are dilutive. Potential common shares consist of shares issuable upon the exercise of stock options and warrants (using the treasury stock method). Dilutive net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive.

The following potentially dilutive, common share equivalents were excluded from the calculation of diluted net loss per common share because their effect was antidilutive for each of the periods presented:

| | November 30, | |
|-----------------------------------|--------------|-----------|
| | 2014 | 2013 |
| Options to purchase common stock | 3,364,077 | 3,378,818 |
| Warrants to purchase common stock | 2,562,045 | 2,082,045 |
| Total | 5,926,122 | 5,460,863 |

(3) Marketable Securities

Marketable securities classified as available for sale consisted of the following:

| | November 30, 2014 | | | |
|-------------------------------|-------------------|-----------------------------|-----------------------------|-------------|
| Available for sale securities | Amortized Cost | Gross Unrealized Gain | Gross Unrealized Loss | Fair Value |
| Certificates of Deposit | \$3,764 | \$ — | \$ (2) |) \$ 3,762 |
| Corporate Bonds | 13,645 | — | (4) |) 13,641 |
| Total | \$17,409 | \$ — | \$ (6) |) \$ 17,403 |

CERES, INC. AND SUBSIDIARIES**Notes to Condensed Consolidated Financial Statements (Unaudited)****(In thousands, except share and per share data)**

| Available for sale securities | August 31, 2014 | | Gross Unrealized Loss | Fair Value |
|-------------------------------|-------------------|-----------------------------|-----------------------------|------------|
| | Amortized Cost | Gross Unrealized Gain | | |
| Certificates of Deposit | \$4,244 | \$ — | \$ (4) | \$ 4,240 |
| Commercial Paper | 5,249 | — | — | 5,249 |
| Corporate Bonds | 15,157 | — | (7) | 15,150 |
| Total | \$24,650 | \$ — | \$ (11) | \$ 24,639 |

At November 30, 2014 and August 31, 2014, \$60 of the certificates of deposits included above are recorded as cash and cash equivalents on the condensed consolidated balance sheets.

All marketable securities at November 30, 2014 and August 31, 2014 are due to mature in one year or less.

(4) Inventories

Inventories consisted of the following:

| | November 30, 2014 | August 31, 2014 |
|------------------------|----------------------|--------------------|
| Seed - work in process | \$ - | \$ 20 |
| Seed inventory | 53 | 64 |
| Unharvested biomass | 737 | - |
| Total inventories | \$ 790 | \$ 84 |

(5) Property and Equipment

Property and equipment are summarized as follows:

| | November 30, 2014 | August 31, 2014 |
|----------------------------------------------------------------|----------------------|--------------------|
| Land | \$ 43 | \$ 43 |
| Automobiles and trucks | 1,037 | 1,113 |
| Buildings | 1,215 | 1,215 |
| Office, laboratory, farm and warehouse equipment and furniture | 12,683 | 12,718 |
| Leasehold improvements | 5,659 | 5,659 |
| | 20,637 | 20,748 |
| Less accumulated depreciation | (17,870) | (17,752) |
| Property and equipment, net | \$ 2,767 | \$ 2,996 |

(6) Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

| | November 30, 2014 | August 31, 2014 |
|--------------------------------------|----------------------|--------------------|
| Accounts payable | \$ 1,899 | \$ 1,406 |
| Accrued payroll and related expenses | 1,353 | 2,303 |
| Research and development contracts | 164 | 123 |
| Accrued grower commitments | - | 54 |
| Other | 327 | 392 |
| | \$ 3,743 | \$ 4,278 |

CERES, INC. AND SUBSIDIARIES**Notes to Condensed Consolidated Financial Statements (Unaudited)****(In thousands, except share and per share data)****(7) Long-Term Debt**

Long-term debt is summarized as follows:

| | November 30, 2014 | August 31, 2014 |
|---------------------------------|----------------------|--------------------|
| Capital leases | \$ 55 | \$ 88 |
| Less current portion | (55) | (70) |
| Long term debt (capital leases) | \$ - | \$ 18 |

(8) Stock-Based Compensation***Stock Option and Stock Issuance Plans***

The Company has established three equity plans: the Ceres, Inc. 2000 Stock Option/Stock Issuance Plan (2000 Plan), the Ceres, Inc. 2010 Stock Option/Stock Issuance Plan (2010 Plan) and the Amended and Restated Ceres, Inc. 2011 Equity Incentive Plan (2011 Plan, and collectively with the 2000 Plan and the 2010 Plan, Equity Plans). The Equity Plans provide for grants of Incentive Stock Options (ISOs) to employees and Nonqualified Stock Options (NSOs), stock and restricted stock to employees, directors, and consultants. In addition, the 2011 Plan provides for the grant of other equity based awards such as restricted stock units, stock appreciation rights and deferred stock to employees, directors and consultants. The option term, as determined by the Company's Board of Directors, may not exceed ten years. Vesting, also determined by the Company's Board of Directors, generally occurs ratably over four to five years. ISOs and NSOs may be granted at a price per share not less than the fair market value at the date of grant.

Stock-based compensation expense included in operating expenses are as follows:

Three months ended

Edgar Filing: Ceres, Inc. - Form 10-Q

| | November 30, | |
|----------------------------------------------|--------------|--------|
| | 2014 | 2013 |
| Stock-based compensation expense | \$ 619 | \$ 913 |
| Fair value changes of collaboration warrants | (4) | 9 |
| | \$ 615 | \$ 922 |

There were no stock options exercised during the three months ended November 30, 2014 and 2013.

Stock Option Activity

The following table summarizes the stock option transactions under the Equity Plans during the three months ended November 30, 2014:

| | Shares | Weighted Average Exercise Price |
|------------------------------------------|-----------|---------------------------------------|
| Options outstanding at August 31, 2014 | 3,172,948 | \$ 5.83 |
| Options granted | 241,416 | 0.53 |
| Options forfeited | (50,287) | 6.58 |
| Options outstanding at November 30, 2014 | 3,364,077 | \$ 5.44 |

CERES, INC. AND SUBSIDIARIES**Notes to Condensed Consolidated Financial Statements (Unaudited)****(In thousands, except share and per share data)**

No tax benefits have been recorded on compensation costs recognized for options exercised. As of November 30, 2014, there was \$2,481 of total unrecognized compensation cost related to stock options. That cost is expected to be recognized over a weighted average of 1.94 years. The Company's policy is to issue new shares for options exercised.

Restricted Stock Activity

The following summarizes the restricted stock transactions under the Equity Plans during the three months ended November 30, 2014:

| | Shares | Weighted Average Grant Date Fair Value |
|----------------------------------------------------------------|-----------|-------------------------------------------------|
| Restricted stock outstanding and unvested at August 31, 2014 | 302,751 | \$ 4.07 |
| Restricted stock granted | 73,000 | 0.53 |
| Restricted stock vested | (56,433) | 5.64 |
| Restricted stock forfeited | (4,417) | 1.25 |
| Restricted stock outstanding and unvested at November 30, 2014 | 314,901 | \$ 3.01 |

As of November 30, 2014, there was \$379 of total unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized over a weighted average of 1.14 years.

Stock Activity

There were no stock grants during the three months ended November 30, 2014. During the fiscal year 2014, the Company granted 18,300 shares of common stock under the 2011 Plan with a fair market value of \$0.91 per share. The Company recorded \$16.7 of expense related to this stock grant.

(9) Stockholders' Equity

Common Stock

On March 7, 2014, the Company held its 2014 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation which decreased the total number of shares of common stock of the Company from 490,000,000 to 240,000,000. Holders of the Company's common stock are entitled to dividends as and when declared by the Board of Directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote.

Preferred Stock

Pursuant to the Company's amended and restated certificate of incorporation, the Company is authorized to issue 10,000,000 shares of preferred stock. The Board of Directors has the authority, without action by the Company's stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof.

CERES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands, except share and per share data)

Warrants issued in connection with Noble Agreement

In May 2006, the Company entered into a collaboration agreement with The Samuel Roberts Noble Foundation, Inc. (Noble) (Noble Agreement) to establish a research program (see Note (12)). In connection with this collaboration, the Company granted Noble a warrant to purchase 133,333 shares of the Company's common stock for an exercise price of \$30.00 per share. The original terms were as follows: the warrant vests in equal installments of 33,333 shares on May 19, 2009, May 19, 2011, May 19, 2013, and May 19, 2015, respectively, and shall remain exercisable for a period of two years from the respective vesting dates. These warrants are accounted for at fair value and remeasured until vested. The fair value, including the resulting change in value as a result of remeasurement is being recognized as research and development expense. The inception to date expense recognized with respect to this warrant totals \$624.4 as of November 30, 2014. At November 30, 2014, 99,999 warrants had vested under this arrangement. The fair value of the warrants not yet vested at November 30, 2014, was \$0 using a risk-free rate of 0.68% based on the respective exercise periods of each installment, expected volatility of 68.9%, expected term of 2.47 years based on the respective exercise periods of each installment, which is also the remaining contractual term, and 0% dividend yield.

In June 2011, the Company and Noble agreed to modify the warrants issued to Noble as follows: the warrant vests in equal installments of 33,333 shares on May 19, 2013 and May 19, 2015, respectively and shall remain exercisable until the earliest of a period of five years from the respective vesting dates and May 18, 2017.

Warrants issued in connection with TAMU Agreement

In August 2007, the Company entered into a sponsored research and intellectual property rights agreement with The Texas A&M University System (TAMU) to establish a research program (see Note (12)). In connection with this collaboration, the Company granted TAMU a warrant to purchase 66,666 shares of the Company's common stock for an exercise price of \$30.00 per share. The warrant vests based on certain research and commercialization milestones being met and shall remain exercisable until August 28, 2017. This warrant is accounted for at fair value and remeasured until the vesting targets are met. The fair value, including the resulting change in value as a result of remeasurement is being recognized as research and development expense. The inception to date expense recognized with respect to this warrant totals \$0 as of November 30, 2014. The fair value of the warrants at November 30, 2014 was \$0, using a risk-free rate of 0.88%, expected volatility of 68.8%, expected term of 2.74 years and 0% dividend yield. No warrants have vested under this arrangement as of November 30, 2014.

In December 2011, pursuant to an Amended and Restated Intellectual Property Rights Agreement (IP Rights Agreement) (see Note (12)), the Company issued warrants to TAMU to purchase 66,666 shares of common stock at an exercise price of \$14.30 per share. The warrants expire on September 24, 2026 and, subject to certain conditions, vest in equal installments on the fifth, tenth and fifteenth anniversary of the IP Rights Agreement. The inception to date expense recognized with respect to this warrant totals \$3.1 as of November 30, 2014. The fair value of the warrants at November 30, 2014, was \$8.2, using a risk-free rate of 2.18%, expected volatility of 84.1%, expected term of 11.81 years and 0% dividend yield. No warrants have vested under this arrangement as of November 30, 2014.

Warrants issued in connection with March 10, 2014 registered public offering

On March 10, 2014 the Company issued warrants to purchase an aggregate of 480,000 shares of common stock to certain affiliated designees of the underwriter as part of the underwriter's compensation related to the registered public offering. The warrants are exercisable at any time and from time to time, in whole or in part, beginning on March 4, 2015 and expire on March 4, 2019. The exercise price is \$1.50 per share of common stock. The fair value of these warrants upon issuance was \$305 using a risk free rate of 1.64%, expected volatility 84.2%, expected term of 5 years and 0% dividend yield and was treated as an issuance cost of the common stock.

(10) Income Taxes

No provision for U.S. income taxes has been made, net of the valuation allowance, with the exception of minimum statutory amounts, because the Company has incurred losses since its inception. The Company has deferred tax assets consisting primarily of net operating loss carryforwards that have been fully offset by a valuation allowance.

(11) Commitments and Contingencies

The Company leases certain of its facilities and equipment under various noncancelable operating leases expiring through 2023. The leases on the facilities contains provisions for future rent increases. The Company records monthly rent expense equal to the total of the payments due over the lease term, divided by the number of months of the lease term. The difference between rent expense recorded and the amount paid is credited or charged to deferred rent, which is included in other current liabilities and other non-current liabilities in the accompanying condensed consolidated balance sheets as of November 30, 2014, and August 31, 2014.

CERES, INC. AND SUBSIDIARIES**Notes to Condensed Consolidated Financial Statements (Unaudited)****(In thousands, except share and per share data)**

In connection with one of its facilities leases, the Company received a reimbursement for leasehold improvements of \$270. This reimbursement is a lease incentive which has been recognized as a liability in deferred rent and is being amortized to rent expense on a straight-line basis over the lease term. Total rental expense recognized was \$134 and \$66 for the three months ended November 30, 2014 and 2013, respectively.

Future minimum payments under noncancelable operating leases as of November 30, 2014 are as follows:

| | Operating Leases |
|-------------------------------------------|---------------------|
| Remaining nine months of fiscal year 2015 | \$ 537 |
| 2016 | 680 |
| 2017 | 627 |
| 2018 | 576 |
| 2019 | 624 |
| Total minimum lease payments | \$ 3,044 |

(12) Research Collaboration Agreements

The Company has a number of research agreements with academic collaborators, including among others, TAMU, Noble, and the Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences. In connection with these agreements, the Company receives certain exclusive options or licensing rights to technology and intellectual property developed under these agreements. The Company expenses amounts under these agreements to research and development expense in the period in which the services are rendered. The Company also licenses technology from third parties. Initial payments under these license agreements are capitalized and expensed on a straight-line basis over the license term.

Noble Agreement

In May 2006, the Company entered into a collaboration agreement with Noble to establish a research program. Under the Noble Agreement, the Company agreed to fund certain research activities undertaken by Noble in an amount up to \$3,800 through July 31, 2012 and granted Noble a warrant to purchase 133,333 shares of the Company's common stock for an exercise price of \$30.00 per share (see Note (9)). Additional projects may be added under the agreement, if agreed to by both parties.

Under the collaboration agreement, in August 2012 the Company agreed to fund certain research activities undertaken by Noble through July 31, 2013 and 2014 of \$82.7 and \$85.3 per year, respectively.

TAMU Agreement

In August 2007, the Company entered into a Sponsored Research and Intellectual Property Rights agreement with TAMU to establish a research program. Under the agreement, the Company agreed to fund certain research activities undertaken by TAMU in an amount up to \$5,100 through 2012 and granted TAMU a warrant to purchase 66,666 shares of the Company's common stock for an exercise price of \$30.00 per share (see Note (9)).

On September 24, 2011, the Company entered into an Amended and Restated Sponsored Research Agreement and the IP Rights Agreement with TAMU which both expire on September 23, 2026. The specific research projects and budgets undertaken pursuant to such agreement will be determined by an Executive Committee comprised of two members from each of TAMU and the Company as set forth in the Amended and Restated Sponsored Research Agreement. In December 2011, pursuant to the IP Rights Agreement, the Company issued warrants to TAMU to purchase 66,666 shares of common stock at an exercise price of \$14.30 per share (see Note (9)).

CERES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands, except share and per share data)

Future minimum payments under the Company's research collaboration agreements as of November 30, 2014 are as follows:

| | |
|-------------------------------------------|---------|
| Remaining nine months of fiscal year 2015 | \$623 |
| 2016 | 544 |
| 2017 | 88 |
| | \$1,255 |

(13) Subsequent Events

On December 12, 2014, the Company's Board of Directors adopted a resolution approving a proposal to be presented to the shareholders at the next annual meeting to effect a reverse split of all of the Company's outstanding shares of common stock by a ratio in the range of 1-for-8 and 1-for-11 with the exact range to be determined by the Board. The proposal provides that the Company's Board of Directors shall have sole discretion pursuant to Section 242(c) of the Delaware General Corporation Law to elect, as it determines to be in the Company's best interest, whether or not to effect the reverse stock split before April 27, 2015, such date as the Company is required to comply with the minimum bid price requirements of NASDAQ Listing Rule 5550(a)(2) or to abandon it. If the Company's Board determines that effecting the reverse stock split is in the Company's best interest, the reverse stock split will become effective upon filing of an amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and the other financial information appearing elsewhere in this Quarterly Report on Form 10-Q, the information under the heading "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 20, 2014. This discussion contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements, other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our efforts to develop and commercialize our products, anticipated yields and product performance, our short-term and long-term business strategies, market and industry expectations and future results of operations and financial position, including anticipated cost savings from our plan to align expenditures, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "may", "will", "should", "expect", "plan", "anticipate", "could", "intend", "target", "project", "contemplate", "believe", "estimate", "potential", "continue" or other similar words. We based these forward-looking statements largely on our current expectations and projections about future events or trends that we believe may affect our business and financial performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to materially differ from any future results, performance or achievements expressed or implied by these forward-looking statements. We have described in the "Risk Factors" section in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 20, 2014 and elsewhere in this Quarterly Report on Form 10-Q, the material risks and uncertainties that we believe could cause actual results to differ from these forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which we cannot predict or quantify, you should not rely on these forward-looking statements as guarantees of future results, performance or achievements. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of the filing of this Quarterly Report on Form 10-Q. We undertake no obligation to update publicly, except to the extent required by law, any forward-looking statements for any reason after the date we file this Quarterly Report on Form 10-Q with the SEC to conform these statements to actual results or to changes in our expectations.

Overview

We are an agricultural biotechnology company that develops and markets seeds to produce crops for bioenergy and other markets that utilize plant biomass. We use a combination of advanced plant breeding, biotechnology and bioinformatics to develop seed products that we believe address the limitations of first-generation bioenergy feedstocks, such as corn and sugarcane. These technology platforms, which can increase crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple crops, including food, feed, fiber and fuel crops.

We are pursuing multiple markets for our sorghum products. We market our sweet sorghum hybrids as a “drop-in” feedstock to complement existing feedstock supplies and extend the operating season of Brazilian sugarcane-to-ethanol mills. We also market our high biomass sorghum products to mills and other agri-industrial facilities for use in generating electricity, heat and steam. Biomass feedstocks grown from our seeds can also be used for the production of second-generation biofuels and bio-based chemicals. Due to the similarities among crops developed for bioenergy and those developed for livestock consumption, we believe that certain of our seed products may have application in the hay and forage feed market. Our upstream position in the value chain allows us to be largely independent of the success of any particular conversion technology or end use. The seed industry has historically required very little capital to produce, condition and package seeds, and seeds have typically been priced based on a share of the value they create and thus have generated high gross margins. As a producer of proprietary seeds, we believe we are in one of the most attractive segments of crop production and bioenergy value chain.

We believe crops such as corn, rice and sugarcane can benefit from many of the traits and genetic technologies we are developing for bioenergy crops, such as traits that provide drought tolerance. We have also generated many biotech traits specifically for cereal crops, such as rice, that increase grain yields and provide greater yield stability across different environments. To date, our field evaluations have largely confirmed earlier results obtained in greenhouse and laboratory settings, and we believe that based on these multiple confirmations, we have an industry leading biotech trait technology pipeline, with applications in food, feed, fiber and fuel crops.

We market and sell our seed products under our Blade brand. In certain crops, including corn, rice and sugarbeet, we have out-licensed a portion of our traits and gene technology to existing market participants and continue to pursue opportunities to out-license these technologies, among other go-to-market strategies. We also market our proprietary genome viewer software, known as Persephone, to plant and biomedical researchers.

We believe that the strength of our technology has been validated by our receipt of multiple competitive grants as well as collaborations with leading companies in crop science, such as Syngenta Biotechnology and Bayer CropScience. We also have significant intellectual property rights to our technology platforms, traits and seed products.

We operate in one segment, and accordingly, our results of operations are presented on a consolidated basis. To date the majority of our revenue and expense has been denominated in U.S. dollars and foreign currency fluctuations have not had a significant impact on our historical results of operations. As we continue to penetrate the Brazilian market and enter markets outside the United States, we expect our product sales will be made in local currencies and accordingly, that foreign currency fluctuations will have a greater impact on our operating results.

We generate revenues from government grants, research and development collaboration agreements and from product sales. We began selling products in 2008 and, while our product sales have been minimal to date, we expect product sales to eventually become the primary source of our revenues. We expect future product revenues to include a combination of seed sales, biomass sales, and trait fees, similar to current business models used for food crops incorporating biotech traits. As we continue to develop traits for our products, we expect that a significant portion of our product revenues will be generated from the sale of seeds that include our traits.

We have invested significantly in research, development and technology and applied our proprietary technology platforms to energy crops and expect to continue to invest in research and development focusing on sorghum, as well as traits with significant market potential in other crops, like corn, rice and sugarcane. Our other operating expenses are related to selling, general and administrative expenses incurred to establish and build our market presence and business infrastructure.

Seed inventory costs are computed on a first-in, first-out basis and valued at the lower of cost or market with any excess cost recognized during the period within cost of product sales. When inventory costs exceed expected market value due to obsolescence or lack of demand, inventory write-downs are recorded for the difference between the cost and the market value in the period based on our evaluation of such inventory. The recoverability of our seed inventory is dependent on increased customer adoption and acceptance. At November 30, 2014, we also incurred additional costs for crop management services and support, which have been capitalized to Inventory as unharvested biomass costs, subject to lower of cost or market adjustments. We expect to recover these biomass costs from the associated revenue generated by biomass sales.

Historically, we have funded our operations from payments from collaborators and government grants and the proceeds from issuances of common stock, convertible preferred stock, warrants, convertible notes and debt financing. We have experienced significant losses as we invested heavily in research and development and marketing, and those costs have exceeded revenues. As of November 30, 2014, we had an accumulated deficit \$309.9 million. We expect to incur additional losses related to the continued development and expansion of our business including research and development, seed production and operations, and sales and marketing. There is no assurance that we will achieve profitable operations, or if achieved, they can be sustained on a continued basis.

In July 2014, our Brazilian subsidiary was selected for a competitive grant and a multi-year credit facility to fund a product development project for sorghum and sugarcane for up to approximately 85 million reais, or 31.6 million U.S. dollars, under the government's *PAISS Agricola* program. The project consists of a non-repayable grant of up to approximately 10 million reais, or 3.7 million U.S. dollars, and a government-subsidized credit facility for up to approximately 67.5 million reais, or 25.1 million U.S. dollars. The company is expected to fund up to approximately 7.5 million reais, or 2.8 million U.S. dollars, of the project. (Based on the Exchange Rate of the Central Bank of Brazil, on January 8, 2015, one Real was equivalent to .37 U.S. Dollars.) We have completed the required application and have received approval in principle for the grant and credit facility. Subject to the completion of a final project plan review and customary documentation, we expect to draw the first tranche of the non-repayable grant during our second fiscal quarter. We are currently evaluating the terms and requirements of the credit facility and expect to make a decision on the size and timing of the first tranche of the loan by our third fiscal quarter. The credit facility is subject to customary documentation and credit approval, and financial guarantees to be provided by Ceres.

On October 11, 2013, we commenced the implementation of a plan intended to further align expenditures with our near-term commercial opportunity in Brazil, shift Northern Hemisphere sorghum breeding activities from College Station, Texas to a more appropriate location, de-emphasize research and development for U.S. cellulosic feedstocks, reduce costs and conserve cash.

Commercial Evaluations of Our Sorghum Products

Since 2010, we have completed various field evaluations of our sorghum products in Brazil with approximately 50 ethanol mills, mill suppliers and agri-industrial facilities. During this time, our sorghum seeds were planted and harvested using existing equipment and fermented into ethanol or combusted for electricity generation without retrofitting or altering the existing mills or industrial facilities. We believe these experiences have demonstrated the “drop-in” nature of both our sweet and high-biomass sorghum products, and along with higher yielding products in our pipeline, will serve as the basis for expanded adoption of these product lines as a feedstock for ethanol and power production in Brazil and other markets.

With industrial processing of sorghum feedstock generally well established in Brazil, we believe that field performance — primarily yields of sugars that can be fermented to ethanol — will largely determine the scale and pace at which our current and future sweet sorghum products will be adopted. Based on industry feedback, we believe that minimum average yields in the range of 2,500 to 3,000 liters of ethanol per hectare will be necessary to achieve broad adoption. While we achieved yields in this range in the 2013-2014 growing season in Brazil with multiple products in multiple regions, we expect that the 2014-2015 growing season in Brazil will be necessary to validate results. Additional growing seasons beyond the 2014-2015 season may be required to fully demonstrate this yield performance across numerous geographies and for our products to gain broad adoption. For our high-biomass types, based on industry feedback, we believe that minimum average yields per hectare in the range of 30 to 40 metric tons of biomass, measured at 50% moisture content, will be necessary to achieve broad adoption. Recent water shortages and increasing demand for power in Brazil have led to a spike in electricity prices. We believe these market conditions have made biomass yields as low as approximately 28 metric tons per hectare economically attractive at current electricity prices.

Plantings for the 2014-2015 sorghum growing season in Brazil have been largely completed with more than 50 customers, which include, among others, ethanol mills and multi-mill conglomerates that we estimate are collectively responsible for more than 30% of the sugarcane crushed in Brazil. Total plantings of our sorghum products in Brazil cover more than 4,000 hectares, compared to approximately 1,000 hectares planted the previous season. The increase in planted area is due primarily to increased demand for high biomass sorghum for power generation. Plantings also include small, multi-hybrid evaluations designed to determine yield potential, identify the best performing hybrids for specific regions and demonstrate various crop management practices. Following a dry start to the growing season, which delayed some plantings, growing conditions have been generally favorable to date across most evaluation regions. Overall plantings were lower than our original forecast of 5,000 hectares due to some weather delays at the beginning of the season, which provided less time to plant, and our subsequent decision not to plant outside our recommended timeframe. Harvests are expected to begin in March and continue through May.

To meet immediate demand for biomass for power generation and to facilitate the development of a supply chain for sorghum biomass, we are providing agronomy and crop management services for certain customers this season under our sales incentive and promotional programs, which include offtake agreements for sorghum biomass produced under our direction or management. Revenue for these plantings will be based upon yields of biomass per hectare rather than seed sales. We expect to incur increased costs of sales for crop management and agronomy support services provided under the programs, which we expect to recover from the associated revenue generated by biomass sales. However, depending on biomass yields per hectare, the costs of these programs may exceed our revenues. The majority of high biomass sorghum hectares this season were planted under these sales incentive and promotional programs. We expect to recognize the majority of our product revenues for the 2014-2015 season during our fiscal third and fourth quarters.

Forage Sorghum in the U.S. and Brazil

In addition to utilizing our sorghum seed products to grow feedstock for bioenergy, we have initiated sales of our sorghum for use as livestock feed and forage, following successful evaluations in the U.S. and Brazil. The results of evaluations this year in the U.S. and Brazil will help determine the commercial potential of this market for our current and future seed products.

Biotechnology Traits

Biotechnology, also known as genetic engineering, allows us to precisely add traits not readily achievable through conventional breeding methods. In most cases, the same trait can be added to multiple crops with similar effect. Our strategy is to focus on genes that have shown large, step increases in performance, and whose benefits are largely maintained across multiple species. For example, in December 2014, we completed a second year of field evaluations of our multi-gene biotech traits in corn. These multi-gene combinations demonstrated a yield advantage of approximately 25% over controls in many of our research-scale field evaluations. Trials were conducted in two different climatic regions in China through our development collaboration with the Chinese Academy of Agricultural Sciences. We have selected the best multi-gene combinations for broader field evaluations in 2015. Favorable results from small-scale evaluations and research settings are not a guarantee of future commercial performance, and further evaluations will be necessary to confirm results.

We believe that our results, including results from our corn trials in China, represent an important step forward in crop biotechnology. We have optimized the expression of our genes in a more precise and sophisticated manner than is usually the case. In addition, we believe that combining genes together, to either create a stronger trait or combine complementary traits, provides the best approach to generate high impact advantages, such as increased grain yield or drought tolerance. We have also developed a new high-throughput, low-cost approach to empirically evaluate large numbers of promising genes and related control components and to select the best combinations for deployment in a crop. We are deploying this multi-gene trait development system internally and believe there may be opportunities to out-license the system, known as iCODE, to other crop biotechnology companies.

Persephone Bioinformatics Software

We have established our Persephone bioinformatics software as a preeminent genome browser, displacing incumbent solutions at major life science companies. The software includes a number of proprietary data management optimizations to quickly fetch and render very large datasets. This speed enables more dynamic visualizations, intuitive discovery and greater insights into genomics data. We believe that our direct experience using Persephone internally and our ability to continually develop and launch new versions with additional features and functions will enable us to further establish our market position in the plant sciences and expand into new markets, such as biomedical research and diagnostics. We intend to increase the number of customers utilizing our Persephone software as their primary genome browser through both client-server installations at major life science companies as well as a planned Software as a Service (SaaS) edition that targets the larger market of individual researchers. We plan to evaluate a beta version and prepare for the commercial launch of our SaaS edition during our second fiscal quarter.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates and assumptions on historical experience and on various other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The results of our analysis form the basis for making assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies involve significant areas of management's judgments and estimates in the preparation of our financial statements.

Revenue Recognition

Revenues are recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) transfer of product or technology has been completed or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. To date, our primary source of revenues has been derived from research collaborations and government grants and, to a lesser extent, product sales.

Product Sales

Product sales are derived from sales of seeds, trait fees, crop management services and biomass sales. Product sales are recognized, net of discounts and allowances, once passage of title and risk of loss have occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met.

Collaborative Research and Government Grants

From time to time, we have entered into research and development collaboration agreements with third parties including a large agriculture supplier, a consumer goods conglomerate and several biofuel producers. In addition, we have received grants from government agencies such as the United States Department of Energy and the United States

Department of Agriculture. The research and development collaboration agreements typically provide us with multiple revenue streams, which may include upfront, non-refundable fees for licensing certain of our technologies, fees for research and development activities, and contingent milestone payments upon achievement of contractual criteria.

Technology License Fees. For collaboration agreements in which we have continuing involvement, license fees are recognized on a straight-line basis over the term of the arrangement. Licensing fees are non-refundable and not subject to future performance.

Government Grants. We receive payments from government entities in the form of government grants. Government grants generally provide us with cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period, as well as an allocated portion of our overhead expenses. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that substantially all conditions under which the government grants were provided have been met and we only have perfunctory obligations outstanding.

Research and Development Fees. Generally, fees for research and development activities are recognized as the services are performed over the performance period, as specified in the respective agreements. Certain of our collaboration agreements require us to deliver research data by specific dates and that the collective program plan will result in reaching specific crop characteristics by certain dates. For such arrangements, we recognize revenues based on the approximate proportional performance of services under the agreement, but the revenue recognized cannot exceed the payments that have accrued to us to date under the agreement. The research and development period is estimated at the inception of each agreement and is periodically evaluated.

Milestone Payments. Fees that are contingent upon achievement of substantive performance milestones at inception of the agreement are recognized based on the achievement of the milestone, as defined in the respective agreements.

We recognize deferred revenue to the extent that cash received under the collaboration agreement is in excess of the revenues recognized related to the agreement since the work under the agreement has not yet been performed, or the work has not been fully completed as prescribed in the statement of work at the balance sheet date, which is classified as other current liabilities on the accompanying condensed consolidated balance sheets.

Stock-Based Compensation

We account for stock-based compensation arrangements with employees using fair value methods which require the recognition of compensation expense for costs related to all stock-based payments. The fair value methods require us to estimate the fair value of stock-based payment awards on the date of grant. We use an option pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period. The fair value of restricted stock granted to employees is based on the grant date value of the underlying stock. We account for stock options issued to non-employees based on the estimated fair value of the awards using the option pricing model. The measurement of stock-based compensation to non-employees is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in our condensed consolidated statements of operations during the period the related services are rendered.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To the extent that an impairment indicator has occurred, recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the reporting periods

presented herein there was no impairment.

Results of Operations

The following table sets forth our condensed consolidated results of operations for the periods shown (in thousands):

| | Three months ended November 30, | |
|----------------------------------------------|------------------------------------|-------------|
| | 2014 | 2013 |
| Revenues: | | |
| Product sales | \$ - | \$ 20 |
| Collaborative research and government grants | 400 | 743 |
| Total revenues | 400 | 763 |
| Cost and operating expenses: | | |
| Cost of product sales | 442 | 1,309 |
| Research and development | 2,504 | 4,414 |
| Selling, general and administrative | 3,441 | 3,260 |
| Total cost and operating expenses | 6,387 | 8,983 |
| Loss from operations | (5,987) | (8,220) |
| Interest expense | (3) | - |
| Interest income | 18 | 16 |
| Loss before income taxes | (5,972) | (8,204) |
| Income tax expense | (1) | (1) |
| Net loss | \$ (5,973) | \$ (8,205) |

Comparison of the Three Months Ended November 30, 2014 and 2013***Revenues***

| | Three Months Ended November 30 | | |
|----------------------------------------------|--------------------------------------------|--------|-----------|
| | 2014 | 2013 | Change |
| | (In thousands) | | |
| Product sales | \$ - | \$ 20 | \$ (20) |
| Collaborative research and government grants | 400 | 743 | (343) |
| Total revenue | \$ 400 | \$ 763 | \$ (363) |

Our total revenues decreased by \$0.4 million to \$0.4 million for the three months ended November 30, 2014 compared to the same period in the prior year. Revenue under our various collaborative research and government grants decreased by \$0.3 million primarily due to the completion of work scheduled under various grants and collaborations. We expect to recognize the majority of our product revenues for the 2014-2015 growing season in Brazil during our fiscal third and fourth quarters.

Cost and Operating Expenses

| | Three Months Ended November 30, | | |
|-------------------------------------|---------------------------------------|---------|-----------|
| | 2014 | 2013 | Change |
| | (In thousands) | | |
| Cost of product sales | \$442 | \$1,309 | \$(867) |
| Research and development | 2,504 | 4,414 | (1,910) |
| Selling, general and administrative | 3,441 | 3,260 | 181 |
| Total cost and operating expenses | \$6,387 | \$8,983 | \$(2,596) |

Cost of Product Sales

Our cost of product sales decreased by \$0.9 million to \$0.4 million for the three months ended November 30, 2014 compared to the same period in the prior year. The decrease was primarily due to reduced operating expenses of \$0.5 million and reduced personnel and related expenses in the U.S. of \$0.4 million.

Research and Development Expenses

Our research and development expenses decreased by \$1.9 million to \$ 2.5 million for the three months ended November 30, 2014 compared to the same period in the prior year. In the U.S., research and development expenses decreased by \$1.4 million primarily due to reduced personnel and related expenses of \$1.2 million and reduced external research and development expenses of \$0.2 million. In Brazil, research and development expenses decreased by \$0.5 million primarily due to reduced personnel and related expenses, and from a reduction in the total number of research field trial locations established for the 2014-2015 growing season.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses increased by \$0.2 million to \$3.4 million for the three months ended November 30, 2014 compared to the same period in the prior year. The increase was primarily due to increased personnel and related expenses of \$0.2 million in Brazil. In the U.S., legal and professional fees increased by \$0.3 million which was offset by reduced personal and related expenses of \$0.3 million.

Interest Expense and Interest Income

| | Three Months Ended November 30, 2014 2013 Change | | |
|------------------|-----------------------------------------------------------------|-------|---------|
| | (In thousands) | | |
| Interest expense | \$ (3) | \$ - | \$ (3) |
| Interest income | 18 | 16 | 2 |
| Total | \$ 15 | \$ 16 | \$ (1) |

Interest Income

Interest income increased by \$2,000 during the three months ended November 30, 2014 compared to the same period in the prior year. The increase was due to the returns on invested balances in Brazil.

Liquidity and Capital Resources

Since our inception, we have incurred significant net losses, and, as of November 30, 2014, we had an accumulated deficit of \$309.9 million. We expect to incur additional losses related to the continued development and expansion of our business including research and development, seed production and operations, and sales and marketing. There is no assurance that we will achieve profitable operations, or if achieved, that we can sustain them on a continued basis.

We plan to finance its operations for the next 12 months with cash and marketable securities on hand, and with cash inflows from collaboration and grant funding and from product sales. We intend to seek additional funds through collaborations, licensing arrangements, public or private debt or equity financings or government programs, and may also seek to reduce expenses related to our operations. We cannot assure you that such additional funds from collaborations, licensing arrangements, public or private debt or equity financings or government programs will be available to us or that the terms would be acceptable to us. There is also no assurance that we will achieve profitable operations, or if achieved, that we can sustain them on a continued basis.

On March 10, 2014, we completed a registered public offering of 23,000,000 shares of our common stock (including 3,000,000 shares purchased by the underwriter upon the exercise in full of their right to purchase up to an additional 3,000,000 shares to cover over-allotments) at a price to the public of \$1.00 per share, resulting in net proceeds of approximately \$20.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. We also issued warrants to purchase an aggregate of 480,000 shares of our common stock to certain affiliated designees of the underwriter as part of the underwriter's compensation. The warrants are exercisable at any time and from time to time, in whole or in part, beginning on March 4, 2015 and expire on March 4, 2019. The exercise price is \$1.50 per share of common stock.

In the first quarter of fiscal 2014, management commenced certain actions to extend our available working capital. On October 11, 2013, we commenced a plan intended to further align our expenditures with our near-term commercial opportunity in Brazil, shift Northern Hemisphere sorghum breeding activities from College Station, Texas to a more appropriate location, deemphasize research and development for U.S. cellulosic feedstocks, reduce costs and conserve cash. These measures, which included a workforce reduction that impacted 16 positions in the U.S., were completed by May 31, 2014.

Cash Flows

| | For the three months ended November 30, 2014 2013 (In thousands) | |
|--------------------------------|-----------------------------------------------------------------------------------|-------------|
| Net cash (used in) provided by | | |
| Operating activities | \$ (6,293) | \$ (5,676) |
| Investing activities | \$ 7,104 | \$ 4,040 |
| Finance activities | \$ (23) | \$ (46) |

Net cash outflows of \$6.3 million from operating activities during the three months ended November 30, 2014 primarily resulted from our net loss of \$6.0 million, which included non-cash items of \$0.6 million in stock based compensation expense and \$0.2 million in depreciation expense.

Net cash outflows of \$5.7 million from operating activities during the three months ended November 30, 2013 primarily resulted from our net loss of \$8.2 million, which included non-cash items of \$1.3 million including \$0.4 million in depreciation expense and \$0.9 million in stock-based compensation expense. The net cash inflow change in our operating assets and liabilities was \$1.2 million during the three months ended November 30, 2013.

Net cash provided by investing activities of \$7.1 million during the three months ended November 30, 2014 was due to net marketable securities activity of \$7.2 million, which was partially offset by \$0.1 million used to purchase property and equipment.

Net cash provided by investing activities of \$4.0 million during the three months ended November 30, 2013 was due to net marketable securities activity of \$4.4 million, which was partially offset by \$0.4 million used to purchase property and equipment..

Net cash used by financing activities of \$23,000 during the three months ended November 30, 2014 was due to repayments on capital leases.

Net cash used by financing activities of \$46,000 during the three months ended November 30, 2013 was due to repayments on capital leases.

Off-Balance Sheet Arrangements

As of November 30, 2014, we had no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.

Seasonality

The sale of seeds is dependent upon planting and growing seasons, which vary from year to year, and are expected to result in both highly seasonal patterns and substantial fluctuations in quarterly sales and profitability. Our product sales for the year ended August 31, 2014 and for the three months ended November 30, 2014 were minimal and, accordingly, we have not yet experienced the full nature or extent to which our business may be seasonal. We expect that the sale of our seeds in Brazil will typically be higher in our first and second fiscal quarters, due to the timing of the planting decisions made by our customers. As we increase our sales in our current markets, and as we expand into new markets in different geographies, it is possible we may experience different seasonality patterns in our business. Weather conditions and natural disasters, such as heavy rains, hurricanes, hail, floods, tornadoes, freezing conditions, drought or fire, also affect decisions by our customers about the types and amounts of seeds to plant and the timing of harvesting and planting such seeds. Disruptions that cause delays by our customers in harvesting or planting can result in the movement of orders to a future quarter, which would negatively affect the quarter and cause fluctuations in our operating results.

Inflation

We believe that inflation has not had a material impact on our results of operations for the three months ended November 30, 2014 and 2013, respectively. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We are exposed to the effect of interest rate changes, foreign currency fluctuations and changes in commodity prices. We are also exposed to changes in the general economic conditions in the countries where we conduct business, which currently is substantially all in the United States and Brazil.

Interest Rate Risk

As of November 30, 2014 and August 31, 2014, our exposure to risk for changes in interest rates primarily related to our cash equivalents and marketable securities. We have investments in money market funds, commercial paper and corporate bonds, which all have relatively short term maturities. Accordingly, our interest income fluctuates with short term market conditions. All marketable securities are classified as available for sale and are expected to be liquid. Due to the relatively short-term nature of our investments, we do not believe that there would be a significant negative impact to our consolidated financial position or results of operations as a result of interest rate fluctuations in the financial markets. While we believe our cash equivalents do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits. We cannot assure you that we will not experience losses on these deposits.

Foreign Currency Risk

We have foreign currency risks related to our operating expenses denominated in currencies other than the U.S. Dollar. Changes in exchange rates between the U.S. Dollar and other currencies will result in increases or decreases in our costs and earnings, and also may affect the book value of our assets outside the United States. To date, most of our contracts have been entered into in the United States and accordingly have been denominated in U.S. Dollars. Going forward we anticipate that our sales will be denominated in the local currency of the country in which the sale occurs. In addition, our operating expenses to date have been denominated in the currencies of the countries in which our operations are located, primarily the United States and Brazil.

Through November 30, 2014, the fluctuations in the Brazil Real for our operations in Brazil had no adverse impact on our results of operations as the U.S. Dollar has been strengthening against the Brazil Real. As our international operations in Brazil grow, our results of operations and cash flows will become increasingly subject to fluctuations due to changes in the foreign currency exchange rates. In periods when the U.S. dollar declines in value as compared to the Brazil Real, our foreign-currency based expenses increase when translated into U.S. dollars. To date, we have not hedged the risks associated with foreign currency exchange exposure. As the risks associated with fluctuations in the Brazil Real become greater, we will continue to reassess our approach to managing this risk.

Commodity Risk

Our exposure to market risk for changes in commodity prices currently is minimal. As our commercial operations grow, our exposure will relate mostly to the demand side as our customers are highly exposed to fluctuations in prices of sugar and crude oil and somewhat exposed to fluctuations in agricultural commodities, especially soybean. For example, if the price of sugar, which is produced from sugarcane and which cannot be produced from sweet sorghum today, rises significantly relative to the price of ethanol, it may become more profitable for ethanol mill operators to grow sugarcane even in adverse conditions, such as through the expansion of sugarcane fields to marginal land or the extension of the sugarcane harvesting season. During sustained periods of significantly higher sugar prices, demand for our seeds may decrease, which could materially and adversely affect our operating results. We are also indirectly exposed to fluctuations in soft commodities prices like soybean when we negotiate production contracts with seed producers. We currently do not use derivative financial instruments to hedge any price volatility of agricultural commodities.

Item 4. Controls and Procedures.

(a) Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosures.

We conducted an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(b) and 15d-15(b) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of November 30, 2014.

(b) Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of August 31, 2014 based on the guidelines established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our internal control over financial reporting includes policies and procedures that provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Based on the results of our evaluation, our management concluded that our internal control over financial reporting was effective as of August 31, 2014. We reviewed the results of management's assessment with our Audit Committee.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may

deteriorate.

Because we are an "emerging growth company" as defined in the JOBS Act, we are not currently required to comply with the auditor attestation requirements related to internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act.

(c) Changes in Internal Control

No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarterly period ended November 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

28

PART II: OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in litigation relating to claims arising out of our operations. We are not currently a party to any material litigation or other material legal proceedings. We may, however, be involved in material legal proceedings in the future. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows.

Item 1A. Risk Factors.

You should carefully consider the risks and uncertainties set forth in “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on November 20, 2014, together with all of the other information set forth in this Quarterly Report on Form 10-Q. If any of these risks actually occur, our business, financial condition, results of operations and future prospects could be materially and adversely affected. There have been no material changes to the risks discussed in the Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Sales of Unregistered Securities

None.

(b) Use of Proceeds from Public Offering of Common Stock

On February 27, 2012, we completed our initial public offering. We sold 5,750,000 shares of common stock at a price to the public of \$13.00 per share, which included the underwriters' exercise in full of their option to purchase 750,000 additional shares. The offer and sale of our common stock in our initial public offering was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-174405), which was declared effective by the SEC on February 21, 2012. We raised approximately \$65.2 million in net proceeds after deducting

underwriting discounts and commissions of \$5.2 million and other offering costs of \$4.9 million. There has been no material change in the planned use of proceeds from our initial public offering as described in our Prospectus dated February 21, 2012 and filed with the Securities and Exchange Commission.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.

(a) The exhibits in the accompanying Exhibit Index on page E-1 are filed or furnished as part of this Quarterly Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Ceres, Inc.

By: /S/ PAUL KUC

Paul Kuc

Chief Financial Officer

(Principal Financial Officer)

Date: January 13, 2015

EXHIBIT INDEX

Number Description

- 31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), of the Securities Exchange Act of 1934, as amended.
- 31.2 Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), of the Securities Exchange Act of 1934, as amended.
- ¹ 32.1 Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.
- #101 Financial statements from the Quarterly Report on Form 10-Q of Ceres, Inc. for the quarterly period ended November 30, 2014, formatted in XBRL: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations (iii) the Condensed Consolidated Statement of Comprehensive Loss, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) the Notes to the Condensed Consolidated Financial Statements.

¹ This certification is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

E-1